Early Phase Cancer Immunotherapy

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

Acest volum, o revizuire de ultima generatie a studiilor clinice de faza timpurie pentru imunoterapia cancerului, discuta despre selectarea biomarkerilor, strategiile combinatorii si siguranta sau toxicitatea acestora, determinarea dozarii de faza 2, punctele finale in stabilirea pseudoprogresiei radiografice, selectia histologiei, si imunoterapeutice noi, in legatura cu imunoterapia cancerului in faza incipienta.